Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Equity Ratio (2016 - 2025)

Rein Therapeutics filings provide 10 years of Equity Ratio readings, the most recent being 0.7 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 19.93% year-over-year to 0.7, compared with a TTM value of 0.7 through Dec 2025, down 19.93%, and an annual FY2025 reading of 0.7, down 19.93% over the prior year.
  • Equity Ratio hit 0.7 in Q4 2025 for Rein Therapeutics, down from 0.86 in the prior quarter.
  • The five-year high for Equity Ratio was 0.95 in Q1 2021, with the low at 0.7 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.89 (2022), compared with a mean of 0.88.
  • The sharpest move saw Equity Ratio soared 98.06% in 2021, then dropped 19.93% in 2025.
  • Year by year, Equity Ratio stood at 0.91 in 2021, then fell by 6.55% to 0.85 in 2022, then grew by 9.58% to 0.93 in 2023, then dropped by 5.68% to 0.87 in 2024, then dropped by 19.93% to 0.7 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.7, 0.86, and 0.84 for Q4 2025, Q3 2025, and Q2 2025 respectively.